Skip to main content
Figure 7 | BMC Complementary and Alternative Medicine

Figure 7

From: Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells

Figure 7

Zyflamend’s effects on protein expression of pErk and acetyl-CBP/p300 in a time dependent manner, and on p21 expression ± Zyflamend in the presence or absence of the HDAC inhibitor U0126. (A) CWR22Rv1 cells were treated with Zyflamend (200 μg/mL) and the expression of p-Erk and acetyl-CBP/p300 was plotted over time (0–60 min, n = 3 for each time point). The data was analyzed by ANOVA. Data points with different letters (p-Erk) are different at p < 0.05. With regards to Ac-CBP/p300, the only data point different from t = 0 is identified with an asterisk (*). Data are presented as the mean ± SD. (B) Western blot of p21 in CWR22Rv1 cells treated ± Zyflamend (200 μg/mL) in the presence or absence of the HDAC inhibitor U0126 (2 μM) for 24 hr.

Back to article page